A Phase I Study of G3139 Subcutaneous in Solid Tumors

Summary

Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or central intravenous line. The route of administration limits the convenience of treatment, and catheter-related complications have been reported. This study is designed to evaluate the pharmacokinetics and safety of G3139 administered by subcutaneuous injection.

Timeline

Start

2005-12

Primary completion

—

Completion

2006-12

Drugs

Indications